Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Inclusion Criteria: * Diagnosis of MM by International Myeloma Working Group Criteria * In first or second complete or partial remission or stable refractory but not actively progressing myeloma according to the classifications provided by The Center for International Blood \& Marrow Transplant Research * Received at least 2 cycles of lenalidomide therapy * Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem cell transplant (ASCT) * At least 2 weeks since last exposure to lenalidomide * Eastern Cooperative Oncology Group performance status of 0 or 1 * Prior to the start of mobilization: * white blood cell count \>/= 2.5 x 10\^9/L * absolute neutrophil count \>/= 1.2 x 10\^9/L * platelet count \>/=100 x 10\^9/L * creatinine clearance \>/= 30mL/minute * If childbearing potential, must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization; female patients will undergo pregnancy test prior to stem cell mobilization therapy Exclusion Criteria: * Had prior autologous or allogeneic transplantation * Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF for mobilization * Failed previous hematopoietic stem cell collections or collection attempts * Received radiation therapy to the pelvic area * Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization * Had received experimental therapy within 4 weeks of enrolling in study * Current or prior history of other malignancies, excluding basal cell carcinoma of the skin